Diligence memo · auto-generated · as of July 2, 2026
Intrinsic Therapeutics Inc
Intrinsic Therapeutics Inc looks fair against its niche peers and is quiet on financing cadence.
Businessfiled
Intrinsic Therapeutics Inc operates in Pharma, based in WOBURN.
Sub-sector tags: pharma.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Intrinsic Therapeutics Inc has raised $219M in disclosed capital across 9 recorded rounds, aggregated from public filings. Its latest round is modeled as Series C (a $40M–$100M round).
Largest single filing: $55M on 2023-11-30.
Most recent recorded round closed around 2023-11-30.
Valuation (modeled)modeled
Provath models Intrinsic Therapeutics Inc at approximately $595M (range $180M–$981M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Fair. Modeled value is 0.94× the median modeled value of Series C Pharma companies in 2022–2024 (7 peers) — value vs value, same stage and era. Within the normal band (94% of peer median) for its niche.
Financing rhythm & timingmixed
Historic cadence: a new round about every 18 months.
Last raise 2.6 yr ago; this sector typically re-raises about every 16 months.
Slightly overdue versus sector cadence.
The last round stepped up 10.1× from the prior — scaling.
Comparablesmixed
Capital scale ranks ahead of 98% of Pharma peers (310 compared).
Modeled value ranks above 87% of those peers.
Closest niche peers: Circle Pharma, Inc., Averna Therapeutics Inc., Soleno Therapeutics Inc, Progentos Therapeutics, Inc., Digital Therapeutics, Inc..
Peoplefiled
21 named people on file across officers, directors and signatories.
Risks & flagsmixed
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.